NeOnc Technologies Holdings, Inc.
NTHIHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeNeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. At a $87.4M market cap, NeOnc Technologies Holdings, Inc. ranks as a micro-cap company within healthcare. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Market Cap
$87.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.47
EPS (TTM)
$-1.84
EPS (Fwd)
$-0.75
ROE
—
ROA
-354.6%
Cash
$138,601
Total Debt
$346,053
Free CF
-$1.6M
52W Change
-30.4%
Annual Financials
Cash vs Debt
Where NTHI stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NTHI finished 47.88% below its 150-day moving average ($7.06) and 52.27% below its 200-day moving average ($7.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTHI overbought or oversold?
At the July 15, 2026 close, NTHI's RSI(14) was 18.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $139K in cash, though total debt stands at $346K. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$1.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $20K (2022) to $40K (2025), reflecting a 100% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for NeOnc Technologies Holdings, Inc. and its sector.